Equillium, Inc.
Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.
EQ | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 2223 AVENIDA DE LA PLAYA, 92037 LA JOLLA
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Equillium, Inc. is a clinical-stage biotechnology company that develops novel therapeutics for severe autoimmune and inflammatory disorders. The company leverages a deep understanding of immunobiology to create treatments aimed at restoring the immune system's balance in patients with high unmet medical needs. Its pipeline features a first-in-class multi-cytokine inhibitor platform utilizing structured-domain peptides to selectively target disease-driving cytokines. Another key asset is EQ504, a potent and selective AhR modulator with a non-immunosuppressive mechanism of action. Equillium's research and development efforts target applications in various fields, including gastroenterology, dermatology, and rheumatology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Equillium, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Equillium, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Equillium, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
